Sunovion has launched the Utibron Neohaler indacaterol/glycopyrrolate DPI for the treatment of COPD in the United States, the company announced. Sunovion acquired the US rights to the Utibron, Seebri, and Arcapta Neohalers from Novartis in December 2016.
Utibron Neohaler, which is marketed as Ultibro Breezhaler outside of the US, was approved by the FDA in October 2015; the Seebri Neohaler glycopyrrolate DPI was approved at the same time. The company says that it plans to launch Seebri and will begin promoting Arcapta Neohaler indacaterol DPI, which was launched in the US in March 2012, within the next year.
Sunovion Executive VP and Chief Commercial Officer David Frawley commented, “Sunovion is pleased to bring to market Utibron Neohaler, an important dual-bronchodilator handheld inhaler, that is a new combination therapy now available for the millions of people with COPD in the United States. As part of our commitment to people living with COPD, Sunovion has built a broad COPD portfolio including nebulized and handheld treatment options for patients at various stages of COPD.”
Read the Sunovion press release.
